Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to assess generalizability of the US FDA Label for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in the GWTG-HF Registry

Next Previous
X
Search
Trial Profile

A study to assess generalizability of the US FDA Label for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in the GWTG-HF Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms GWTG-HF

    • Most Recent Events

    • 31 Oct 2022 According to a Cytokinetics media release, analyses from the registry will be presented at the American Heart Association Scientific Sessions 2022.
    • 15 Nov 2021 Results assessing Incident Dialysis and Acute Kidney Injury among medicare beneficiaries after hospitalization for heart failure presented at the American Heart Association Scientific Sessions 2021
    • 17 May 2021 Results assessing the outcomes of patients with heart failure across the spectrum of kidney function, presented at the 70th Annual Scientific Session of the American College of Cardiology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top